Overview

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2002-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole